J. M. Coindre, Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group, J. Clin. Oncol, vol.14, pp.869-877, 1996.

A. Italiano, Trends in survival for patients with metastatic soft-tissue sarcoma, Cancer, vol.117, pp.1049-1054, 2011.

M. Von-mehren, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Canc. Netw, vol.16, pp.536-563, 2018.

F. Chibon, Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity, Nat. Med, vol.16, pp.781-787, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-02438669

M. L. Ballinger, Monogenic and polygenic determinants of sarcoma risk: an international genetic study, Lancet Oncol, vol.17, pp.1261-1271, 2016.

R. L. Flynn, Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors, Science, vol.347, pp.273-277, 2015.

A. G. Malykh, Identification of new alternative lengthening of telomeres (ALT)-positive cancer cell lines using the C-circle assay, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), 2015.

(. Philadelphia and . Pa, Cancer Res, vol.75, p.3768, 2015.

T. C. Chou and P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul, vol.22, pp.27-55, 1984.

B. O'carrigan, Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies, J. Clin. Oncol, vol.34, p.2504, 2016.

M. Dillon, A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A), Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, vol.77, p.84, 2017.

L. Mei, J. Zhang, K. He, and J. Zhang, Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand, J. Hematol. Oncol, vol.12, p.43, 2019.

T. N. Moiseeva, An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication, Proc. Natl. Acad. Sci. USA, vol.116, pp.13374-13383, 2019.

C. M. Heaphy, Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes, Am. J. Pathol, vol.179, pp.1608-1615, 2011.

K. I. Deeg, I. Chung, C. Bauer, and K. Rippe, Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition, Front. Oncol, vol.6, p.186, 2016.

K. T. Bieging, S. S. Mello, and L. Attardi, Unravelling mechanisms of p53-mediated tumour suppression, Nat. Rev. Cancer, vol.14, pp.359-370, 2014.

E. Fokas, Targeting ATR in DNA damage response and cancer therapeutics, Cancer Treat. Rev, vol.40, pp.109-117, 2014.

A. M. Weber and A. J. Ryan, ATM and ATR as therapeutic targets in cancer, Pharmacol. Ther, vol.149, pp.124-138, 2015.

P. Nghiem, P. K. Park, Y. Kim, C. Vaziri, and S. L. Schreiber, ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation, Proc. Natl. Acad. Sci. USA, vol.98, pp.9092-9097, 2001.

N. Sangster-guity, B. H. Conrad, N. Papadopoulos, and F. Bunz, ATR mediates cisplatin resistance in a p53 genotype-specific manner, Oncogene, vol.30, pp.2526-2533, 2011.

P. M. Reaper, Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR, Nat. Chem. Biol, vol.7, pp.428-430, 2011.

G. Pérot, Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics, Am. J. Pathol, vol.177, pp.2080-2090, 2010.

F. K. Middleton, J. R. Pollard, and N. J. Curtin, The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo-and radiosensitisation, Cancers (Basel), vol.10, p.275, 2018.

M. Savina, Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study, BMC Med, vol.15, p.78, 2017.

A. Laroche, Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas, J. Hematol. Oncol, vol.10, p.84, 2017.